anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypertension is by far the dominant reversible risk factor dwarfing most others in the pathogenesis of chronic kidney disease (CKD) and diastolic left ventricular dysfunction (DVD), two archetypes of chronic age-related diseases, which are rampant in ageing societies in epidemiological transition. Home blood pressure telemonitoring (HTM) is a recommended approach in the diagnosis and management of hypertension. Urinary peptidomic profiling (UPP) holds great promise in individualising prevention and treatment of CKD and DVD and associated complications, such as coronary heart disease. Making use of these modern technologies, UPRIGHT-HTM is an investigator-initiated randomised clinical trial with a patient-centred design, for the first time, comparing HTM combined UPP (experimental group) to HTM alone (control group) in risk profiling and as guide to starting or intensifying management of risk factors to prevent established disease. The trial will run in Europe, sub-Saharan Africa and South America. Eligible patients, aged 55-75 years old, are asymptomatic, but have three or more CKD- or DVD-related risk factors, preferably including hypertension, type 2 diabetes mellitus, or both, and do have internet skills. The primary endpoint consists of a composite of new-onset intermediate endpoints (microalbuminuria, progression of CKD, diabetic or hypertensive retinopathy, electrocardiographic or echocardiographic left ventricular hypertrophy or DVD and hard outcomes (cardiovascular mortality and non-fatal complications, including myocardial infarction, heart failure and stroke). Secondary objectives are demonstrating that combining HTM with UPP is feasible and cost-effective in a multicultural context, defining the molecular signatures of early CKD and DVD, and with help of stakeholders educating and empowering patients. Assuming an accrual time of 1 year, a median follow-up of 4 years, a 10% dropout rate, a 20% risk of the primary endpoint in the control group and 30% risk reduction in the experimental group, requires 1000 patients to be randomised in a 1:1 proportion with the two-sided alpha level and power set 0.05 and 0.80, respectively. The expected outcome is proving the superiority in terms of efficiency and cost-effectiveness of HTM combined with UPP vs HTM alone, which should lead to redesigning the clinical workflow, putting greater emphasis on preventing rather than curing established disease.
The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
Risk Summary

There are no data on the presence of FYARRO in human milk or its effects on the breastfed child or on milk production.

It is not known whether sirolimus is present in human milk. There are no data on its effects on the breastfed infant or milk production. The pharmacokinetic and safety profiles of sirolimus in infants are not known. Sirolimus is present in the milk of lactating rats. There is potential for serious adverse effects from sirolimus in breastfed infants based on mechanism of action [see Clinical Pharmacology (12.1)]. Because of the potential for serious adverse reactions in breastfed infants from FYARRO, advise women not to breastfeed during treatment with FYARRO and for 2 weeks after the last dose.
An imaging system, optionally an intra-oral camera, includes a blue light source and a barrier filter over a camera sensor. Optionally, the imaging system can also take white light images. Optionally, the system includes positively charged nanoparticles with fluorescein. The fluorescent nanoparticles can be identified on an image of a tooth by machine vision or machine learning algorithms on a pixel level basis. Either white light or fluorescent images can be used, with machine learning or artificial intelligence algorithms, to score the lesions. However, the white light image is not useful for determining whether lesions, particularly ICDAS 0-2 lesions, are active or inactive. A fluorescent image, with the fluorescent nanoparticles, can be used to detect and score active lesions. Optionally using a white light image and a fluorescent image together allows for all lesions, active and inactive, to be located and scored, and for their activity to be determined.
Stable emulsions comprising as a base one or more diene conjugated fatty acids. Amino acids and other macromolecules can be used to stabilize the emulsion. The emulsion is also useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the macromolecules. Plant oil extracts, such as conjugated linoleic acid and its acylated derivatives, are useful as the diene conjugated fatty acids that form the base of the stable emulsion. The emulsions formed are useful as nutritional or cosmetic adjuvant for oral based nutrition, skin diseases, cosmetic utility, enhancing oral nutrition, or pharmacological benefit. Methods of producing and using the emulsions are also provided.
OBJECTIVES: I. Determine the toxic effects and feasibility of using filgrastim in promoting hematopoietic recovery and leukemia control after intensive but nonmyeloablative salvage chemotherapy. II. Determine the engraftment kinetics and degree of chimerism achievable.

OUTLINE: The trial will have 2 patient groups. Patients not in remission are assigned to group 1, while patients in remission are assigned to group 2. Then, groups are divided into 2 treatment arms. Patients failing fludarabine therapy receive cytarabine (Ara-C) IV over 2 hours on days -7, -6, -5, -4 and -3. Beginning 4 hours before the first dose of Ara-C, patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) by continuous infusion for 5 days. Patients without prior fludarabine therapy receive fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after the beginning of the fludarabine infusion and continues for 4 hours. Idarubicin IV is given on days -6, -5 and -4. Donors receive filgrastim SC every 12 hours for 2 days prior to stem cell collection. Cells are infused on day 0. For GVHD prophylaxis, all patients receive cyclosporine via continuous IV infusion. Oral cyclosporine is administered once patients tolerate oral feeding and continued for 6 months postinfusion. Then, the dose of cyclosporine is tapered 10% weekly until discontinued. Methylprednisolone begins 5 days after infusion and is gradually tapered.

PROJECTED ACCRUAL: A maximum of 15 patients per arm are likely to be entered in 24 to 36 months.
PURPOSE OF REVIEW: Chronic Postsurgical Pain (CPSP) and the risk for long-term opioid dependency are known complications following major surgery. The idea of Transitional Pain Service (TPS) has been introduced as an interdisciplinary setting to manage pain in the perioperative continuum. We expand on the basic framework and principles of TPS and summarize the current evidence of the TPS and possible interventions to adress postoperative pain. Areas of future work in TPS-related research are discussed.
RECENT FINDINGS: Several studies support the effectiveness of TPS in reducing opioid consumption in the perioperative period and following discharge. Some studies also show an improvement in functional outcome with TPS with patients reporting lower pain severity and pain interference. The TPS aims to halt the progress of acute postoperative pain to CPSP by providing longitudinal support with patient-centered care. While some studies suggest a positive impact of TPS implementation in terms of reduction in postoperative opioid consumption and improvement of some functional outcomes, direct evidence in terms of reduction in the incidence of CPSP is still missing. The cost-effectiveness of TPS and the expansion of TPS through e-health services and digital applications also need to be evaluated.
The human Ether-à-go-go-Related Gene (hERG) encodes a protein responsible for forming the alpha subunit of the IKr channel, which plays a crucial role in cardiac repolarization. The proper functioning of hERG channels is paramount in maintaining a normal cardiac rhythm. Inhibition of these channels can result in the prolongation of the QT interval and potentially life-threatening arrhythmias. Cardiotoxicity is a primary concern in the field of drug development. N-n-Butyl haloperidol iodide (F2), a derivative of haloperidol, has been investigated for its therapeutic potential. However, the impact of this compound on cardiac toxicity, specifically on hERG channels, remains uncertain. This study employs computational and experimental methodologies to examine the inhibitory mechanisms of F2 on hERG channels. Molecular docking and molecular dynamics simulations commonly used techniques in computational biology to predict protein-ligand complexes' binding interactions and stability. In the context of the F2-hERG complex, these methods can provide valuable insights into the potential binding modes and strength of interaction between F2 and the hERG protein. On the other hand, electrophysiological assays are experimental techniques used to characterize the extent and nature of hERG channel inhibition caused by various compounds. By measuring the electrical activity of the hERG channel in response to different stimuli, these assays can provide important information about the functional effects of ligand binding to the channel. The study's key findings indicate that F2 interacts with the hERG channel by forming hydrogen bonding, π-cation interactions, and hydrophobic forces. This interaction leads to the inhibition of hERG currents in a concentration-dependent manner, with an IC50 of 3.75 μM. The results presented in this study demonstrate the potential cardiotoxicity of F2 and underscore the significance of considering hERG channel interactions during its clinical development. This study aims to provide comprehensive insights into the interaction between F2 and hERG, which will may guid us in the safe use of F2 and in the development of new derivatives with high efficiency while low toxicity.
The present invention relates to an improved highly efficient and economic process for large-scale production of Nintedanib and pharmaceutically acceptable salt thereof. The present invention also relates to a single step process that form highly pure Nintedanib through novel intermediates. In this process, Nintedanib base [I] is prepared in a single step, in-situ process wherein the process is performed by formation of two novel intermediates namely, methyl-1-(bromoacetyl)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate and methyl-(3Z)-1-(bromoacetyl)-3-[methoxy(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate. This process avoids use of expensive and hazardous reagent and solvent such as methyl cyclohexane. Further, there is no isolation and analysis of any intermediate after every step completion that made the process easy to perform without much hurdles. Along with the ease of performance, present invention process also gives high-purity final product with high yield. This makes the process highly cost-effective and time-efficient.
At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
The invention relates to a decoloration refining process of total saponins of panax notoginseng leaf ions exchange resin and a resin regeneration method. The decoloration refining process is: first cation-exchange the dilute alcohol water solution of the total saponins of panax notoginseng leaf with resin column and then anion-exchange resin column to decolorate, and when the decoloration is completed, shower the resin column to reduce the loss of total saponins of panax notoginseng leaf and then depressing and steaming the solution and the shower solution, and the product is formed when the leftover is dried. The failure resin can regenerate to get the decoloration ability. The invention method can improve the purity of the produced total saponins of panax notoginseng leaf to more than 90 percent, and improve the exterior color and further be crystallized and purified to get products with high purity. The invention of ion-exchange resin decoloration refining process does not lead into other chemical matters in the process of total saponins of panax notoginseng leaf decoloration, thus avoiding polluting the product again in the process of decoloration. The decoloration process is easy, and the cost is low, while the decoloration effect is obvious and the equipment structure is simple.
PROBLEM TO BE SOLVED: To obtain a water soluble antioxidant having an excellent antioxidant property and/or anti-inflammatory property and provided a method for producing the same. SOLUTION: This method for producing a water soluble antioxidant is to perform a fat-removing treatment of a herb such as that used as a spice by using a liquid carbon dioxide and/or an organic solvent, or carbon dioxide gas in a critical or a supercritical state. An aqueous alcohol is added to a residual oil insoluble portion. An activated carbon is added to the obtained aqueous alcohol-containing extract solution. After an agitation, the activated carbon is removed. By removing water and the alcohol from the obtained solution and the water soluble antioxidant is obtained.
There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with Metformin HCL, USP or any other pharmacologic agent. Dosage of Metformin HCL, USP must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of Metformin HCL, USP is 2550 mg in adults and 2000 mg in pediatric patients (10-16 years of age).

Metformin HCL, USP should be given in divided doses with meals. Metformin HCL, USP should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient.

During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting plasma glucose should be used to determine the therapeutic response to Metformin HCL, USP and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately three months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of Metformin HCL, USP either when used as monotherapy or in combination with sulfonylurea or insulin. 

Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.

Short-term administration of Metformin HCL, USP may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone.
Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through \~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline \& week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
RATIONALE AND OBJECTIVES: Despite being a minimally invasive procedure, biopsy can cause pain and anxiety in patients. Therefore, it is important to reduce the pain and anxiety levels of patients. The present study aims to investigate the effect of music on patient anxiety and pain levels during thyroid fine needle aspiration biopsy.
MATERIALS AND METHODS: In this randomized controlled single-blind study, a validated State-Trait Anxiety Inventory (STAI) consisting of 40 questions in total was used to evaluate patient anxiety rates. The STAI consists of two sections: the state anxiety scale (SAS) measuring instant anxiety and the trait anxiety scale measuring general anxiety. Patients were divided into two groups: Group 1 those who did not listen to music during a biopsy and group 2 those who listened to music. The Visual Analogue Scale was used to evaluate patient pain levels.
RESULTS: Group 1 consisted of 46 patients and Group 2 consisted of 45 patients. After the procedure, the mean SAS scores of Groups 1 and 2 were not significantly different (p = 0.24). However, The state anxiety scale differences, which represents the decrease in pre-procedure and post-procedure anxiety levels (SAS1-SAS2) was statistically different among the groups (p = 0.01). There was a significant difference between the two groups in terms of VAS score distribution (p = 0.01).
CONCLUSION: Music therapy is an easily applicable, cheap, and safe method that can be used to decrease anxiety and pain levels in patients during thyroid biopsy as evidenced by this research.
Cognitive Behaviour Therapy (CBT) is now included in the National Treatment Guidelines in the UK. However, little progress has been made in its delivery in developing countries. Limited resources for the delivery of services and their concentration in big cities have implications for the choice of mode of delivery of treatment. A range of methods are needed to deliver treatment starting from self-help to more specialist interventions. Various CBT based self-help materials have been assessed and shown to be effective in the West . The effectiveness of a Culturally adapted CBT (CaCBT) based guided self-help has been reported, supervised by carers, against care as usual in patients with depression, who attend secondary care in Pakistan .

However, CBT requires a person to be literate, especially for guided self-help or self-help. Pakistan has a literacy rate (ability to read or write) of 58%. An estimated 67% of children study up to primary level (years 1-5) and an estimated 43% have achieved secondary education (up to year 12). These are mostly people from low socio-economic backgrounds who are less likely to suffer from mental health problems such as depression and anxiety. In order to overcome this barrier a video intervention based on self-help intervention is developed. This study aims at testing the feasibility, acceptability and preliminary effectiveness of this intervention.

This will be a rater-blind RCT to evaluate the feasibility and acceptability of video-based guided self-help in addition to treatment as usual (TAU) compared with the waitlist and TAU in Pakistan. This study will employ a pre-post measure and parallel design. It will be conducted from March 2023 to August 2023. Participants who met the inclusion criteria will be randomly allocated to one of the groups, i.e. CBT video plus TAU (intervention group) or waitlist plus TAU (control group) in a 1:1 ratio.
The invention comprises compounds of the general formula <FORM:0969359/C1/1> and their acid addition salts and quaternary ammonium salts wherein A represents a divalent, straight or branched chain saturated hydrocarbon group of 2-6 carbon atoms with at least 2 carbon atoms between the nitrogen atom of the phenothiazine nucleus and the group Z, Z represents an amino, mono- or di-alkylamino group or a nitrogen-containing heterocyclic group attached by a nitrogen atom to the hydrocarbon group A selected from pyrrolidino, morpholino, piperidino piperazino and N-alkylpiperazino, one or more of the carbon atoms of the piperazino groups optionally carrying an alkyl group, and the preparation thereof by (a) reacting 3-nitro phenothiazine with a compound Y-A-Z wherein Y represents the acid residue of a reactive ester, or (b) reacting a phenothiazine of the formula <FORM:0969359/C1/2> with a compound H-Z, or (c) decarboxylating an ester of the general formula <FORM:0969359/C1/3> by heating at a temperature above 100 DEG C. until the evolution of carbon chloride ceases, or (d) cyclising, preferably in a solvent in the form of an N-substituted amide of a lower fatty acid, in the presence of an alkaline condensing agent, a compound of the formula <FORM:0969359/C1/4> where Hal represents halogen (preferably iodine). Acid addition salts include thiophyllinates and salicylates. 3-Dimethylaminopropyl 3-nitro -10- phenothiazinylcarboxylate is prepared by reacting 3-nitrophenothiazine with carbonyl chloride to form 3-nitrophenothiazine -10- carbonyl chloride and reacting this with 3-dimethylaminopropanol. Pharmaceutical compositions useful as antiemetics, antihistaminics and tranquilizers and in the treatment of psychoses comprise the compounds of the invention together with a pharmaceutical carrier or coating. The compositions may be administered orally, rectally or parenterally in the forms of tablets, pills, dispersible powders, granules, suppositories, solutions, suspensions and emulsions. Examples of tablets are given. Specification 969,358 is referred to.
PURPOSE:To obtain a sugar-coated nutrient food capsule having excellent taste, flavor nutrient balance, stability, etc., by applying a sugar coating containing water-soluble nutrient components and water-soluble polysaccharides other than sucrose to a soft gelatin capsule containing oil-soluble nutrient components. CONSTITUTION:A soft gelatin capsule containing oil-soluble nutrient components such as vitamin A, vitamin E, etc. is prepared beforehand. A syrup containing water-soluble polysaccharides such as gum arabic, pectin, agar, etc., and powder for forming sugar coating containing water-soluble nutrient components (e.g. mixed powder of sugar and vitamin C) are sprayed alternately to the gelatin capsule to obtain the objective sugar-coated nutrient food capsule. Since the obtained capsule has a stable coating film of the water-soluble polysaccharide covering the gelatin capsule, the deterioration of the gelatin membrane by the water-soluble nutrient components such as vitamin C can be prevented, and the quality of the food can be maintained stably for a long period.
The present invention relates to a functional cosmetic composition having an effect of preventing and alleviating atopic dermatitis containing an extract of Usnea diffracta Vain. as an active ingredient. According to the present invention, Usnea diffracta Vain. is extracted in solvent under optimal conditions, and thus can be usable for a long time without toxicity and side effects, thereby providing an effect of preventing and alleviating atopic dermatitis. In particular, excellent anti-oxidation and anti-inflammatory activities can be expected by extracting Usnea diffracta Vain. using 70 %(v/v) ethanol and 95 %(v/v) ethanol having high anti-oxidation activity, thereby providing an effect of advantageously using Usnea diffracta Vain. as a functional material related to skin diseases and a cosmetics material related to sensitive skin.